Joseph Maakaron

Joseph Maakaron

Auto-generated profile, based on publicly available information

Joseph Maakaron

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2025 in Blood Advances
Verified
Journal Article
Open access
ABAmneet Bajwa
Amneet Bajwa
QZQiuhong Zhao
Qiuhong Zhao
MGMarcus Geer
Marcus Geer
CLChenyu Lin
Chenyu Lin
JWJames Westholder
James Westholder
TVTimothy Voorhees
Timothy Voorhees
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can affect a significant number of patients. Those who develop refractory CRS or ICANS have few treatment options. Siltuximab, a monoclonal antibody binding circulating interleukin-6, has been proposed to have clinical activity in both CRS and ICANS. We conducted a multicenter retrospective analysis of siltuximab treatment for CRS and ICANS after CAR-T therapy in a real-world cohort from 6 academic centers. Fifty-four patients were evaluated. Sixteen patients had CRS previously treated with tocilizumab and 17 patients had ICANS previously treated with steroids. Of the patients with CRS at the time of siltuximab, 75% had improvement in CRS grade. Of the patients with ICANS at the time of siltuximab, 60% had improvement in ICANS grade. To our knowledge, this is the largest cohort of patients treated with siltuximab for CRS and/or ICANS after CAR-T therapies. Siltuximab appeared to be effective for both CRS and ICANS, including previously treated toxicities. These data support the use of siltuximab in CRS and ICANS as well as provide rationale for future prospective studies.

6 August 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
ABAtallah Baydoun
Atallah Baydoun
JMJoseph E. Maakaron
Joseph E. Maakaron
HHHoussam Halawi
Houssam Halawi
JRJihane Abou Rahal
Jihane Abou Rahal
Ali TaherAli Taher
Ali Taher
Celiac disease, an autoimmune disease once thought to be uncommon, is now being increasingly identified. Our improved diagnostic modalities have allowed us to diagnose more and more patients with atypical symptoms who improve on gluten-free diet (GFD). We discuss here the latest findings regarding the various hematological manifestations of celiac disease and their management. Anemia remains the most common hematological manifestation of celiac disease due to many mechanisms, and can be the sole presenting symptom. Other manifestations include thrombocytosis and thrombocythemia, leukopenia, thromboembolism, increased bleeding tendency, IgA deficiency, splenic dysfunction, and lymphoma. The diagnosis of celiac disease should always be kept in mind when a patient presents with unexplained and isolated hematological finding. Once diagnosed, patients should adhere to GFD and be educated about the potential complications of this disease. We herein present an algorithm for adequate management and follow-up.

19 July 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
FCFrank Cichocki
Frank Cichocki
BZBin Zhang
Bin Zhang
CWCheng-Ying Wu
Cheng-Ying Wu
ECEmily Chiu
Emily Chiu
ADAbderrahman Day
Abderrahman Day
VBVeronika Bachanova
Veronika Bachanova
Allogeneic natural killer (NK) cell adoptive transfer has shown the potential to induce remissions in relapsed or refractory leukemias and lymphomas, but strategies to enhance NK cell survival and function are needed to improve clinical efficacy. Here, we demonstrated that NK cells cultured ex vivo with interleukin-15 (IL-15) and nicotinamide (NAM) exhibited stable induction of l -selectin (CD62L), a lymphocyte adhesion molecule important for lymph node homing. High frequencies of CD62L were associated with elevated transcription factor forkhead box O1 (FOXO1), and NAM promoted the stability of FOXO1 by preventing proteasomal degradation. NK cells cultured with NAM exhibited metabolic changes associated with elevated glucose flux and protection against oxidative stress. NK cells incubated with NAM also displayed enhanced cytotoxicity and inflammatory cytokine production and preferentially persisted in xenogeneic adoptive transfer experiments. We also conducted a first-in-human phase 1 clinical trial testing adoptive transfer of NK cells expanded ex vivo with IL-15 and NAM (GDA-201) combined with monoclonal antibodies in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (NCT03019666). Cellular therapy with GDA-201 and rituximab was well tolerated and yielded an overall response rate of 74% in 19 patients with advanced NHL. Thirteen patients had a complete response, and 1 patient had a partial response. GDA-201 cells were detected for up to 14 days in blood, bone marrow, and tumor tissues and maintained a favorable metabolic profile. The safety and efficacy of GDA-201 in this study support further development as a cancer therapy.

1 January 2013 in Annals of Hepatology
Verified
Journal Article
Open access
PDF file
JMJoseph E. Maakaron
Joseph E. Maakaron
MCMaria Domenica Cappellini
Maria Domenica Cappellini
GGGiovanna Graziadei
Giovanna Graziadei
JAJad Bou Ayache
Jad Bou Ayache
Ali TaherAli Taher
Ali Taher
Patients with thalassemia are often exposed to several risk factors for developing hepatocellular carcinoma (HCC) due to their repeated transfusions. However, even transfusion-independent patients with thalassemia intermedia (TI) can develop HCC, which is mainly attributed to a state of iron overload. We report here two cases and review the literature for the association between TI and HCC. Along with our cases, a total of 36 cases of HCC in thalassemic patients were reported in the literature. Of these, 22 (61%) were TI patients with 6 (27%) of them being hepatitis B and C negative. There was no consistency in their characteristics; therefore, we recommended screening thresholds for HCC in TI patients based on their total liver iron concentration (LIC).

2 April 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JMJoseph E. Maakaron
Joseph E. Maakaron
MZMei-Jie Zhang
Mei-Jie Zhang
KCKaren Chen
Karen Chen
SASunil Abhyankar
Sunil Abhyankar
VBVijaya Raj Bhatt
Vijaya Raj Bhatt
DWDaniel Weisdorf
Daniel Weisdorf

1 September 2020 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JMJoseph E. Maakaron
Joseph E. Maakaron
JRJohn Rogosheske
John Rogosheske
MLMeixiao Long
Meixiao Long
VBVeronika Bachanova
Veronika Bachanova
AMAlice S. Mims
Alice S. Mims